

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

jc997 U.S. PTO
10/042347
01/11/02



In re Application of:

Michael O'REILLY et al.

Art Unit: **Huff, S.**

Serial No.: **To be Assigned**

Examiner: **1642**

Filed: **Herewith**

For: **THERAPEUTIC ANTIANGIOGENIC ENDOSTATIN COMPOSITIONS**

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In accordance with the requirements of 37 C.F.R. §§ 1.56, 1.97-1.98 and MPEP § 609, the Applicant, through his attorneys, hereby brings to the attention of the Examiner the references noted on the attached Form PTO-1449.

The Examiner is respectfully requested to initial in the space adjacent to the listing on Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicant, to confirm that these documents have been considered by the Examiner and made of record in this application.

Since this statement is being filed before the first Office Action has been mailed, no fees are believed to be necessary; however, the Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. 1.16 or 1.17 which may be required during the entire pendency of this application, or to credit any overpayment, to Deposit Account No. 501458.

The above information is presented so that the United States Patent and Trademark Office may, in the first instance, determine any materiality thereof to the claimed invention. See 37 C.F.R. §§ 1.104(a) and 1.106(b) regarding the PTO's duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited " on any patent to issue therefrom.

Respectfully submitted,

Date: January 16, 2002

By:

H. Khalilian
Houri Khalilian,
Registration No. 39,549

KILPATRICK STOCKTON LLP
607 14th Street, N.W., Suite 900
Washington, D.C. 20005
(202) 508-5800
(202) 508-5858 FAX

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
05213-0229	NOT YET AVAILABLE	Filed Herewith
APPLICANT		GROUP
O'REILLY, ET AL		

10/042347
10/11782
U.S. Pro

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
AK	WO 95/29242	11/02/95	PCT		
AL	WO 95/25543	09/28/95	PCT		
AM	WO 93/16716	09/02/93	PCT		
AN	WO 91/10424	07/25/91	PCT		
AO	J58036391	03/03/83	Japan (Abstract)		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	
AR	
AS	
AT	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 05213-0229		SERIAL NO. NOT YET AVAILABLE	FILING DATE Filed Herewith
APPLICANT O'REILLY, ET AL		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
BA	Abe, N. et al., "Identification of a Novel Collagen Chain Represented by Extensive Interruptions in the Triple-Helical Region", <i>Biochem. and Biophys. Resch. Comm.</i> , Vol. 196, No. 2, pp. 576-582 (1993)		
BB	Algire, G.H. et al., "Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants", <i>J. Natl. Canc. Inst.</i> , Vol. 6, pp. 73-85 (1945)		
BC	Angiolillo, A.I. et al., "Human interferon-inducible Protein 10 is a potent inhibitor of angiogenesis in vivo", <i>J. Exp. Med.</i> , Vol. 182, pp. 155-162 (1995)		
BD	Brem, H. et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", <i>J. Neurosurg.</i> , Vol. 74, pp. 441-446 (1991)		
BE	Brockway, W. J. et al., "Measurement of the Binding of Antifibrinolytic Amino Acids to Various Plasminogens", <i>Arch. Biochem. Biophys.</i> , Vol. 151, pp. 194-199 (1972)		
BF	Browne, M.J. et al., "Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells", <i>Fibrinolysis</i> , Vol. 5, pp. 257-260 (1991)		
BG	Cao, Y. et al., "gro- β , α -C-X-C- Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice", <i>J. Esp. Med.</i> , Vol. 182, pp. 2069-2077 (1995)		
BH	Chen, C. et al., "A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors", <i>Canc Resch.</i> , Vol. 55, pp. 4230-4233 (1995)		
BI	Clapp, C. et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis", <i>Endocrinology</i> , Vol. 133, pp. 1292-1299 (1993)		
BJ	Cleary, S. Mulkerrin et al., "Purification and Characterization of Tissue Plasminogen Activator Kringle-2 Domain Expressed in <i>Escherichia coli</i> ", <i>Biochem.</i> , Vol. 28, pp. 1884-1891 (1989)		
BK	Dameron, K.M. et al., "Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1", <i>Science</i> , Vol. 265, pp. 1582-1584 (1994)		
BL	Folkman, J., "Tumor angiogenesis and tissue factor", <i>Nature Med.</i> Vol. 2, pp. 167-168 (1996)		
BM	Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", <i>J. Natl Canc Inst.</i> , Vol. 82, pp. 4-6 (1990)		
BN	Folkman, J., "Angiogenesis in cancer, vascular, rheumatoid and other disease", <i>Nature Medicine</i> , Vol. 1, No. 1, pp. 27-31 (1995)		
BO	Folkman, J., "Long-term culture of capillary endothelial cells", <i>Proc. Natl. Acad. Sci. USA</i> 76, pp. 5217-5221 (1979)		
BP	Folkman, J. et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", <i>Nature</i> , Vol. 339, pp. 58-61 (1989)		
BQ	Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment", <i>Annals of Surgery</i> , Vol. 164, No. 3, pp. 491-501 (1996)		
BR	Folkman, J., "Angiogenesis and Its Inhibitors", <i>Important Advances in Oncology</i> , J.B. Lippincott Company, pp. 42-62 (1985)		
BS	Folkman, J., "Tumor Angiogenesis Therapeutic Implications", <i>NE J. of Med.</i> , No. 18, pp. 1182-1186 (1971)		
EXAMINER		DATE CONSIDERED	
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO. NOT YET AVAILABLE	FILING DATE Filed Herewith GROUP
05213-0229 APPLICANT O'REILLY, ET AL		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
CA	Gavrieli, Y. et al., "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation", <i>J. Cell Biol.</i> , Vol. 119, pp. 493-501 (1992)	
CB	Gimbrone, M.A. et al., "Tumor Growth and Neovascularization An Experimental Model using the Rabbit Cornea", <i>J. Natl. Canc. Inst.</i> , Vol. 52, No. 2 pp. 413-427 (1974)	
CC	Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovascularization", <i>J. of Experi. Med.</i> , Vol. 136, pp. 261-276 (1972)	
CD	Good, D.J. et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin", <i>Proc. Nat. Acad. Sci. USA</i> , Vol. 87, pp. 6624-6628 (1990)	
CE	Grant, D.S. et al., "Scatter factor induces blood vessel formation in vivo", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 1937-1941 (1993)	
CF	Grant, D.S. et al., "Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro", <i>Cell</i> , Vol. 58, pp. 933-943 (1989)	
CG	Gross, J.L. et al., "Modulation of Solid Tumor Growth in vivo by bFGF", <i>Proc. Amer. Assoc. Canc. Resh.</i> , Vol. 31, p. 79 (1990)	
CH	Gross, J.L. et al., "Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro.", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80, pp. 2623-2627 (1983)	
CI	Gunzler, W.A. et al., "The Primary Structure of High Molecular Mass Urokinase from Human Urine", <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , Vol. 363, pp. 1155-1165 (1982)	
CJ	Gupta, S.K. et al., "A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 7779-7803 (1995)	
CK	Holmgren, L. et al., "Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of angiogenesis suppression", <i>Nature Medicine</i> , Vol. 1, No. 2, pp. 149-153 (1995)	
CL	Homandberg, G.A. et al., "Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth", <i>Am. J. Path.</i> , Vol. 120, pp. 327-332 (1985)	
CM	Hori, A. et al., "Suppression of Solid tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor", <i>Canc. Resch.</i> , Vol. 51, pp. 6180-6184 (1991)	
CN	Ingber, D. et al., "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth", <i>Nature</i> , Vol. 348, pp. 555-557 (1990)	
CO	Johansson, J. et al., "Surfactant Protein B: Disulfide Bridges, Structural Properties, and Kringle Similarities", <i>Biochem.</i> , Vol. 30, pp. 6917-6921 (1991)	
CP	Kandel, J. et al., "Neovascularization is Associated with a Switch to the Export of bFGF in the Multistep Development of Fibrosarcoma", <i>Cell</i> , Vol. 66, pp. 1095-1104 (1991)	
CQ	Kim, K. J. et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo", <i>Nature</i> , Vol. 362, pp. 841-844 (1993)	
CR	Kivirikko, S. et al., "Primary Structure of the $\alpha 1$ Chain of Human Type XV Collagen and Exon-Intron Organization in the 3' Region of the Corresponding Gene", <i>J. Bio. Chem.</i> , Vol. 269, No. 7, pp. 4773-4779 (1994)	
EXAMINER		DATE CONSIDERED
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO. NOT YET AVAILABLE	FILING DATE Filed Herewith GROUP
05213-0229 APPLICANT			
O'REILLY, ET AL			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
	DA	Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", <i>Br. J. Cancer</i> , Vol. 35, pp. 347-356 (1977)	
	DB	Lein, W. M. et al., "The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber", <i>Surgery</i> , Vol. 68, No. 2, pp. 334-340 (1970)	
	DC	Lerch et al., "Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations on Their Complex-Forming Properties", <i>European Journal of Biochemistry</i> , Vol. 107, No. 1, pp. 7-13 (1980)	
	DD	Lokker, N.A. et al., "Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-met receptor", <i>Prot. Engin.</i> , Vol. 7, pp. 895-903 (1994)	
	DE	Maione, T.E. et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides", <i>Science</i> , Vol. 247, pp. 77-79 (1990)	
	DF	Marti, D. et al., "Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω -aminocarboxylic acids", <i>Eur. J. Biochem.</i> , Vol. 219, pp. 455-462 (1994)	
	DG	McLean, J.W. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen", <i>Nature</i> , Vol. 330, pp. 132-137 (1987)	
	DH	Menhart, N. et al., "Construction, Expression, and Purification of Recombinant Kringle 1 of Human Plasminogen and Analysis of Its Interaction with ω -Amino Acids", <i>Biochem.</i> , Vol. 30, pp. 1948-1957 (1991)	
	DI	Millauer, B. et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant", <i>Nature</i> , Vol. 367, pp. 576-579 (1994)	
	DJ	Moses, M.A. et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <i>Science</i> , Vol. 248 (1990)	
	DK	Muragaki, Y. et al., "Mouse col 18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 8763-8767 (1995)	
	DL	Muthukaruppan, VR., "Angiogenesis in the Mouse Cornea", <i>Science</i> , Vol. 205, pp. 1416-1418 (1979)	
	DM	Nelson, J. A. et al., "Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis", <i>Canc. Resch.</i> , Vol. 55, pp. 3772-3776 (1995)	
	DN	Nguyen, M. et al., "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane", <i>Microvascular Research</i> , Vol. 47, pp. 31-49 (1994)	
	DO	Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", <i>J. of Nat. Canc. Inst.</i> , Vol. 85, No. 3, pp. 241-242 (1993)	
	DP	O'Reilly et al., "Endogenous Inhibitors of Angiogenesis", <i>Proc. Am. Assoc. Canc. Resch.</i> , Vol. 37, p. 669 (1996)	
	DQ	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", <i>Nature Medicine</i> , Vol. 2, No. 6, pp. 689-692 (1996)	
	DR	O'Reilly et al., "The suppression of Tumor Metastases by a Primary Tumor", <i>Surgical Forum</i> , Vol. XLIV, pp. 474-476 (1993)	
	DS	O'Reilly et al., "Angiostatin A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , Vol. 79, pp. 315-328 (1994)	
	DT	O'Reilly et al., "Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth", <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LIX, pp. 471-482 (1994)	
	DU	Obeso, J. et al., "Methods in Laboratory Investigation/A Hemangioendothelioma-Derived Cell Line Its Use as a Model for the Study of Endothelial Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, p. 159 (1990)	
	DV	Oh, S.K. et al., "Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4229-4233 (1994)	
EXAMINER		DATE CONSIDERED	
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 05213-0229		SERIAL NO. NOT YET AVAILABLE	FILING DATE Filed Herewith
APPLICANT O'REILLY, ET AL		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
EA	Oh, S.P., "Cloning of cDNA and Genomic DNA Encoding Human Type VIII Collagen and Localization of the $\alpha 1$ (XVIII) Collagen Gene to Mouse Chromosome 10 and Human Chromosome 21", <i>Genomics</i> , Vol. 19, pp. 494-499 (1994)		
EB	Parangi, S. et al., "Antiangiogenic therapy of transgenic mice impairs de novo tumor growth", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 2002-2007 (1996)		
EC	Passaniti, A. et al., "Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", <i>Lab. Invest.</i> , Vol. 67, No. 4, pp. 519-528 (1992)		
ED	Ponting et al., "Plasminogen: a structural review", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 3, pp. 605-614 (1992)		
EE	Powell, J. R. et al., "Amino Acid Sequence Analysis of the Asparagine-288 Region of the Carbohydrate Variants of Human Plasminogen", <i>Biochem.</i> , Vol. 22, pp. 923-927 (1983)		
EF	Rastinejad, F. et al., "Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene", <i>Cell</i> , Vol. 56, pp. 345-355 (1989)		
EG	Rehn, M. et al., " $\alpha 1$ (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4234-4238 (1994)		
EH	Rehn, M. et al., "Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts", <i>J. Biol. Chem.</i> , Vol. 270, pp. 5705-4711 (1995)		
EI	Robbins, K.C., "The Plasminogen-Plasmin Enzyme System", <i>Fibrinolysis</i> , pp. 340-357 (1987)		
EJ	Sage, E.H. et al., "Inhibition of Endothelial Cell Proliferation by SPARC is Mediated through a Ca^{2+} -Binding EF-Hand Sequence", <i>J. Cell. Biochem.</i> , Vol. 57, pp. 127-140 (1995)		
EK	Sakamoto, N. et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH ₂ " <i>Canc. Resch.</i> , Vol. 51, pp. 903-906 (1991)		
EL	Sambrook, J. et al., "Expression of Cloned Genes in Escherichia coli", <i>Molecular Cloning Second Edition</i> , Cold Spring Harbor Laboratories Press, pp. 17.37-17.41		
EM	Schaller, J. et al., "Structural Aspects of the Plasminogen of Various Species", <i>Enzyme</i> , 40 pp. 63-69 (1988)		
EN	Shi, G. et al., "Kringle Domains and Plasmin Denaturation", <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 178, No. 1, pp. 360-368 (1991)		
EO	Sottrup-Jensen, L. et al., "The Primary Structure of Human Plasminogen Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Prog. in Chem. Fibrinolysis and Thrombolysis</i> , Vol. 3, pp. 191-209 (1978)		
EP	Srivastava, A. et al., "The Prognostic Significance of Tumorascularity in Intermediate-Thickness (0.76-4.0mm Thick) Skin Melanoma", <i>Am. J. of Path.</i> , Vol. 133, No. 2, pp. 419-424 (1988)		
EQ	Strieter, R.M. et al., "Interferon- γ -inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis", <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 210, pp. 51-57 (1995)		
ER	Studier, W.F. et al., "Use of T7 RNA polymerase to direct expression of cloned genes", <i>Methods Enzymol.</i> , Vol. 85, pp. 60-89 (1990)		
ES	Teicher, B.A. et al., "Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents", <i>Int. J. Canc.</i> , Vol. 57, pp. 1-6 (1994)		
ET	Tolsma, S.S. et al., "Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity", <i>J. Cell Biol.</i> , Vol. 122, pp. 497-511 (1993)		
EU	Van Meir, E. et al., "Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells", <i>Nature Genetics</i> , Vol. 8, pp. 171-176 (1994)		
EV	Voest, E. E. et al., "Inhibition of Angiogenesis in Vivo by Interleukin 12", <i>J. Natl. Can. Inst.</i> , Vol. 87, pp. 581-586 (1995)		
EXAMINER		DATE CONSIDERED	
EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 05213-0229	SERIAL NO. NOT YET AVAILABLE	FILING DATE Filed Herewith
APPLICANT O'REILLY, ET AL		GROUP

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

FA	Walz, D.A. et al., "Amino acid sequence of human prothrombin fragments 1 and 2", <i>Proc. Natl. Acad. Sci.</i> , Vol. 74, pp. 1969-1973 (1977)
FB	Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma", <i>J. Natl. Canc. Inst.</i> , Vol. 84, pp. 1875-1887 (1992)
FC	Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma", <i>Am. J. Path.</i> , Vol. 143, No. 2, pp. 401-409 (1993)
FD	Weidner, N. et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", <i>NE J. of Med.</i> , Vol. 324, No. 1, pp. 1-8 (1991)
FE	Wiman, B. et al., "On the Specific Interaction Between the Lysine-Binding Sites in Plasmin and Complementary Sites In α_2 -Antiplasmin and Fibrinogen", <i>Biochimica et Biophysica Acta</i> . Vol. 579, pp. 142-154 (1979)
FF	Yoshimura, T. et al., "Cloning, Sequencing, and Expression of Human Macrophage Stimulating Protein (MSP, MST1) Confirms MSP as a Member of the Family of Kringle Proteins and Locates the MSP Gene on Chromosome 3", <i>Laboratory of Immunobiology</i> , pp. 15461-15468 (1993)
FG	
FH	
FI	
FJ	
FK	
FL	
FM	
FN	
FO	
FP	

EXAMINER _____ DATE CONSIDERED _____

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 09/315,689

Application Number: 09,515,669

First Named Inventor M. Judah Folkman

First Name/Last Name

Examiner Name **S. H.**

Attorney Docket Number 05213-

Attorney Docket Number 03215-0229 (43170-219534) 8

5 DOCUMENTS

1 DOCUMENTS Date of Publication of Pages, Columns, Lines, Where

tee or Applicant Date of Publication of
Cited Document Pages, Columns, Lines, Where
Relevant Passages or Relevant

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/315,689
Sheet	2	Filing Date	May 20, 1999
		First Named Inventor	M. Judah Folkman
		Group Art Unit	1642
		Examiner Name	S. Huff
		Attorney Docket Number	05213-0229 (43170-219534)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T2
	3	Blezinger, Paul, et al. "Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the Endostatin gene" NATURE BIOTECHNOLOGY, vol.17, April 1999, pp 343-348.		
	4	Dhanabal, Mohanraj, et al.: "Cloning, Expression, and <i>In Vitro</i> Activity of Human Endostatin" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, US ACADEMIC PRESS INC. ORLANDO, FL, vol. 258, no. 258, 1999, pp 345-352.		
	5	Ding, Yuan-Hua, et al.: "Zinc-dependent dimmers observed in crystals of human endostatin" PROC. NATL. ACAD. SCI USA, vol. 95, no. 18, September 1998, pp. 10443-10448.		
	6	O'Reilly, Michael S., et al.: "Endostatin: an Endogenous Inhibitor of Angiogenesis and Tumor Growth" CELL, vol. 88, January 24, 1997, pp. 277-285.		
	7	Sasaki, Takako, et al.: "Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin" THE EMBO JOURNAL, vol. 17, no. 15, August 1998, pp. 4249-4256.		
	8	Ständer, Ludger, et al.: "Isolation and characterization of the circulating form of human endostatin" FEBS LETTERS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 420, no. 420, 1997, pp. 129-133.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.